We are live on ! Find out more

CARL

Carlsmed

CARL

Market cap $425M

15.58 USD

+0.19

1.23%

At close Updated Sep 18, 4:00 PM EDT

Pre-market

After hours

15.58

0.00

0%

1 day

1.23%

5 days

4.63%

1 month

4.7%

3 months

54.72%

6 months

41.89%

Year to date

33.96%

1 year

1.5%

5 years

7.45%

10 years

7.45%

About: Carlsmed Inc is a commercial-stage medical technology company focused on developing AI-enabled personalized solutions for spine surgery. The company operates as a single operating and reportable segment engaged in the design, manufacture, and marketing of its Aprevo technology platform, which provides customized surgical planning and implants for lumbar and cervical spine fusion procedures, mainly sold to hospitals and ambulatory surgical centers.

Employees: 127

Healthcare Health Information Services

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 8.3%

Neutral 83.3%

Negative 8.3%

Carlsmed, Inc. Files Patent Infringement Lawsuit against DeGen Medical

CARLSBAD, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” ), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today filed a patent infringement lawsuit against DeGen Medical, Inc. (“DeGen”) in the United States District Court for the District of South Carolina Florence Division.

Carlsmed, Inc. Files Patent Infringement Lawsuit against DeGen Medical

Carlsmed, Inc. Announces Chief Operating Officer Appointment

CARLSBAD, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that Jeff Bertolini has been promoted to the role of Chief Operating Officer, effective immediately. Jeff joined Carlsmed in September 2024, most recently serving as the Company's Senior Vice President, Operational Excellence and previously, Vice President of Advanced Manufacturing Technologies. Prior to joining Carlsmed, Jeff held senior leadership positions in operations and technology at SI-BONE, NuVasive, and US Surgical.

Carlsmed, Inc. Announces Chief Operating Officer Appointment

Carlsmed Eyes Growth as Cervical Launch, Medicare Shift Boost Spine Platform

Carlsmed NASDAQ: CARL outlined its strategy for expanding its personalized spine-surgery platform, citing clinical data, reimbursement changes and a planned cervical product launch as potential drivers of growth during a Bank of America small- and mid-cap virtual event.

Carlsmed Eyes Growth as Cervical Launch, Medicare Shift Boost Spine Platform

Carlsmed, Inc. (CARL) Presents at Bank of America SMID Cap Virtual Conference Transcript

Carlsmed, Inc. (CARL) Presents at Bank of America SMID Cap Virtual Conference Transcript

Carlsmed, Inc. (CARL) Presents at Bank of America SMID Cap Virtual Conference Transcript

Carlsmed, Inc. (CARL) Q2 2026 Earnings Call Transcript

Carlsmed, Inc. (CARL) Q2 2026 Earnings Call Transcript

Carlsmed, Inc. (CARL) Q2 2026 Earnings Call Transcript

Carlsmed Q2 Earnings Call Highlights

Carlsmed NASDAQ: CARL reported second-quarter 2026 revenue of $18.9 million, up 57% from $12.1 million a year earlier, as growth in its aprevo lumbar platform and contributions from its newer cervical offering lifted procedure volumes.

Carlsmed Q2 Earnings Call Highlights

Zacks Investment Research

Carlsmed, Inc. (CARL) Reports Q2 Loss, Beats Revenue Estimates

Carlsmed, Inc. (CARL) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $1.47 per share a year ago.

Carlsmed, Inc. (CARL) Reports Q2 Loss, Beats Revenue Estimates

Carlsmed® Reports Second Quarter 2026 Financial Results and Raises Full-Year Guidance

Second quarter 2026 revenue of $18.9 million, representing 57% growth year-over-year Full year 2026 revenue guidance raised to $74 million to $78 million CARLSBAD, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today reported financial results for the second quarter ended June 30, 2026.

Carlsmed® Reports Second Quarter 2026 Financial Results and Raises Full-Year Guidance

Carlsmed Announces Favorable Reimbursement for aprevo® lumbar Procedures

Centers for Medicare & Medicaid Services (CMS) Fiscal Year 2027 Inpatient Final Rule creates three new Medicare Severity-Diagnosis Related Groups (MS-DRGs), with favorable reimbursement for Carlsmed aprevo® Lumbar spine fusion procedures Centers for Medicare & Medicaid Services (CMS) Fiscal Year 2027 Inpatient Final Rule creates three new Medicare Severity-Diagnosis Related Groups (MS-DRGs), with favorable reimbursement for Carlsmed aprevo® Lumbar spine fusion procedures

Carlsmed Announces Favorable Reimbursement for aprevo® lumbar Procedures

Zacks Investment Research

Will Carlsmed, Inc. (CARL) Report Negative Earnings Next Week? What You Should Know

Carlsmed, Inc. (CARL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Carlsmed, Inc. (CARL) Report Negative Earnings Next Week? What You Should Know

See News Rankings

Price charts implemented using Lightweight Charts™